Abstract
In the article titled “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” [1], the captions of Figures 3 and 4 were incorrect. The corrected captions for Figures 3 and 4 appear below. (Figure Presented). Figure 4: Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total insulin glargine 100 IU/ml (DDD based) over time across Europe.
| Original language | English |
|---|---|
| Article number | 9757348 |
| Journal | BioMed Research International |
| Volume | 2023 |
| DOIs |
|
| State | Published - 2023 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Erratum: Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver